|
Synonyms: MG531 | Nplate®
romiplostim is an approved drug (FDA (2008), EMA (2009))
Compound class:
Peptide or derivative
Comment: This drug is a thrombopoietin receptor agonist, although its peptide sequence does not resemble that of the endogenous peptide thrombopoietin. Romiplostim is known as a peptibody, a fusion between the Fc portion of immunoglobulin and a therapeutic peptide. In this case the drug exists as a heterodimer. The carboxy terminal 14 amino acid residues of this peptibody constitute the thrombopoietin receptor binding domain (single letter amino acid code: IEGPTLRQWLAARA).
|
| No information available. |
Summary of Clinical Use  |
| Romiplostim is used to increase the platelet count in patients suffering from chronic idiopathic thrombocytopenic purpura (ITP), a disease characterised by autoimmune destruction of platelets. As of December 2018 the FDA permits use of romiplostim in pediatric ITP patients ≥1 year of age. |
| Mechanism Of Action and Pharmacodynamic Effects |
| Romiplostim acts by a similar mechanism to thrombopoietin, activating intracellular transcriptional pathways via the thrombopoietin receptor (the product of the MPL oncogene, c-MPL) which results in increased production and differentiation of megakaryocytes, the platelet precursors. The aim of treatment is to have platelets produced more quickly than they are destroyed by the patient's own immune system. |
| External links |
|
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA) |
